Researchers staple semaglutide fragments to build tougher GLP-1 scaffolds
A structure-guided program produced several peptide constructs with improved serum and proteolytic stability, but receptor function remains to be demonstrated.
VOL. 01AUGUST 2026
The NewsroomMenu
Latest News
The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
A 26-person sleep-peptide pilot reports signals—not a verdict
PeptiSleep improved selected questionnaire domains in a small single-blind study, while sleep diaries and several other outcomes did not separate from placebo.
AI can propose antimicrobial peptides faster; biological validation remains the bottleneck
A new field review separates models that identify antimicrobial sequences from those that generate candidates—and details why prediction is not proof of a drug.
Radiolabeled peptide therapy beats everolimus on progression-free survival in COMPETE
The 309-patient phase 3 comparison favored lutetium-177 edotreotide for advanced somatostatin-receptor-positive neuroendocrine tumors.
A muscle-preservation trial tests what is lost alongside tirzepatide weight
Adding the myostatin antibody apitegromab preserved more lean mass without materially changing total weight loss in a 102-person phase 2 study.
Petrelintide’s phase 1 data put a long-acting amylin analogue into the weight-loss race
Two randomized early-stage trials found a roughly 10-day half-life and weight loss of up to 8.6% after 16 weeks, with gastrointestinal events remaining the central tolerability question.
An adjuvant-free IL-17A peptide vaccine clears its first human safety study
A 20-person phase 1 trial produced an immune response without severe or serious adverse events, but it was designed to establish an early safety signal—not clinical benefit.